The potential resistance mechanisms to CD19 CAR therapies include CD19 gene mutation or downregulation, cancer cell selection by an immune response, lineage transdifferentiation, or fratricide killing of CAR T cells as a result of trogocytosis [100]. Here, CD19 is linked to cancer.